Werarak Peerawong, Kiratisin Pattarachai, Thamlikitkul Visanu
Division of Infectious Disease, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
J Med Assoc Thai. 2010 Jan;93 Suppl 1:S126-38.
Nosocomial pneumonia (NP), hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), is an important cause of morbidity and mortality in hospitalized patients. One of the factors contributing to a high mortality rate of HAP and VAP could be antibiotic resistance among the causative agents.
To determine prevalence of bacterial pathogens clinical features, risk factors of HAP and VAP, antimicrobial resistance among major respiratory pathogens, clinical implication of antimicrobial resistance, antimicrobial regimens used, and treatment outcomes of adult patients with HAP and VAP at Siriraj Hospital.
This was a prospective, hospital-based, active surveillance study on HAP and VAP in hospitalized adults at Siriraj Hospital from December 2007 to March 2009. The patients with HAP and VAP were followed prospectively until they expired or were discharged from the hospital.
One hundred and forty-six adult patients were included. Seventy percent of the patients were males with the mean age of 70.8 years. HAP was accounted for 24.7% and VAP 75.3%. Most of the patients (82.9%) had late-onset HAP or VAP with the median day of onset of pneumonia of 11 days. Two third of the patients were hospitalized in general medical wards. Bronchopneumonia was observed in 53.4% and multilobar pneumonia in 24.7%. A. baumanni was the most common isolated pathogen and 92.3% of them were multidrug-resistant (MDR) or pandrug-resistant (PDR). The other common isolated pathogens were K. pneumoniae, P. aeruginosa and methicillin-resistant S. aureus (MRSA). Carbapenem was the most commonly used initial antibiotic (45.9%) followed by colistin (21.9%) and cephalosporins (21.1%). The concordance of initial antibiotics was 58.9%. Antibiotics were modified 43.8% of the patients. Colistin was the most commonly used modified antibiotic followed by carbapenem. The modified antibiotics were concordant with isolated bacteria in 98.4%. The patients received mechanical ventilators in 81.5% with the median ventilator day of 10 days. At the initial response (72 hours after antibiotic therapy), an improvement was 56.8% and a mortality rate due to pneumonia was 14.4%. Death due to pneumonia at the end of treatment was 42.5%. The 30-day mortality from pneumonia was 45.9%. There were no significant differences in the outcomes of pneumonia between HAP and VAP. The factors associated with PDR-organisms were late-onset hospital-acquired pneumonia and previous carbapenem usage within 72 hours. Septic shock and bilateral lung involvement were significantly associated with unfavorable outcomes at 72 hours. Septic shock, severe sepsis, and previous carbapenem usage within 72 hours were significantly associated with mortality at the end of treatment and at 30 days after developing pneumonia.
HAP and VAP remain to be very important hospital-acquired infections at Siriraj Hospital. The isolated pathogens are usually multidrug-resistant and the mortality rate remains high. The local data on prevalence of the isolated pathogens and their antibiotic susceptibility may help clinicians choose more appropriate initial antibiotics in order to improve the outcome and to decrease the emergence of resistant organisms.
医院获得性肺炎(NP)、医院内获得性肺炎(HAP)和呼吸机相关性肺炎(VAP)是住院患者发病和死亡的重要原因。导致HAP和VAP高死亡率的因素之一可能是病原体中的抗生素耐药性。
确定诗里拉吉医院成年HAP和VAP患者的细菌病原体流行情况、临床特征、危险因素、主要呼吸道病原体的抗菌药物耐药性、抗菌药物耐药性的临床意义、使用的抗菌治疗方案以及治疗结果。
这是一项于2007年12月至2009年3月在诗里拉吉医院对住院成人HAP和VAP进行的前瞻性、基于医院的主动监测研究。对HAP和VAP患者进行前瞻性随访,直至其死亡或出院。
纳入146例成年患者。70%的患者为男性,平均年龄70.8岁。HAP占24.7%,VAP占75.3%。大多数患者(82.9%)发生迟发性HAP或VAP,肺炎发病的中位天数为11天。三分之二的患者入住普通内科病房。观察到支气管肺炎占53.4%,多叶肺炎占24.7%。鲍曼不动杆菌是最常见的分离病原体,其中92.3%为多重耐药(MDR)或泛耐药(PDR)。其他常见的分离病原体为肺炎克雷伯菌、铜绿假单胞菌和耐甲氧西林金黄色葡萄球菌(MRSA)。碳青霉烯类是最常用的初始抗生素(45.9%),其次是黏菌素(21.9%)和头孢菌素(21.1%)。初始抗生素的一致性为58.9%。43.8%的患者更换了抗生素。黏菌素是最常用的更换抗生素,其次是碳青霉烯类。更换后的抗生素与分离出的细菌的一致性为98.4%。81.5%的患者接受了机械通气,机械通气的中位天数为10天。在初始反应(抗生素治疗72小时后)时,病情改善的占56.8%,因肺炎导致的死亡率为14.4%。治疗结束时因肺炎死亡的占42.5%。肺炎的30天死亡率为45.9%。HAP和VAP之间的肺炎结局无显著差异。与PDR病原体相关的因素是迟发性医院获得性肺炎和72小时内曾使用碳青霉烯类。感染性休克和双侧肺部受累与72小时时的不良结局显著相关。感染性休克、严重脓毒症和72小时内曾使用碳青霉烯类与治疗结束时及肺炎发生后30天的死亡率显著相关。
在诗里拉吉医院,HAP和VAP仍然是非常重要的医院获得性感染。分离出的病原体通常具有多重耐药性,死亡率仍然很高。关于分离病原体的流行情况及其抗生素敏感性的本地数据可能有助于临床医生选择更合适的初始抗生素,以改善治疗结果并减少耐药菌的出现。